CORCEPT THERAPEUTICS INC
At today's price, CORCEPT THERAPEUTICS INC (CORT) is priced for today's economics sustained for ~9.3 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
- Corcept is a specialty pharma built on one approved drug, Korlym for Cushing's syndrome, now transitioning into a second act as relacorilant (branded Lifyorli) wins approval in platinum-resistant ovarian cancer and seeks a Cushing's label. The stage is the key: this is a profitable single-product company priced like a pipeline story. - At $79.92 no valuation family reaches the price on current economics. Inverting it implies growth held at the self-funding ceiling for roughly nine years, so th
Is CORT overvalued? See what's priced in →
338 institutional managers reported holding CORT in 13F filings for the quarter ended 2026-03-31. Together they hold about 76% of the company; the top 10 hold 50%. 63 opened new positions that quarter. Held by BlackRock, Vanguard Group, Renaissance Technologies, among others. On the short side, 8.6M shares were sold short as of the 2026-06-15 count, about 8% of shares outstanding (8.8 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
CORT has cut its share count 10.2% over the past five years, spending $214.35M on repurchases. It pays no dividend. Cash returned over the past three years: $43.15M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at CORT over the trailing three years: 2026: 2 buys totaling $3.31M. 12 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
CORT's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-03 | +25.0% | -15.2% |
| 2023-11-02 | -9.9% | +0.2% |
| 2024-02-16 | -6.2% | +1.1% |
| 2024-05-02 | +7.5% | +21.7% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
CORT's latest 8-K filings: 2026-06-17 (items 8.01, 9.01); 2026-06-03 (items 8.01); 2026-05-28 (items 5.02, 5.07, 9.01); 2026-04-30 (items 2.02, 7.01, 9.01); 2026-03-25 (items 8.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.